UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Dianthus Therapeutics, Inc.

(Name of Issuer)

 

Common stock, $0.001 par value per share

(Title of Class of Securities)

 

252828108

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

5AM Ventures VII, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) x (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,199,228 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

1,199,228 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,199,228 (2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

4.1% (3)

12.

Type of Reporting Person (See Instructions)

 

PN

       
(1)This Schedule 13G is filed by 5AM Ventures VII, L.P. (“Ventures VII”), 5AM Partners VII, LLC (“Partners VII”), 5AM Opportunities II, L.P. (“Opps II”), 5AM Opportunities II (GP), LLC (“Opps II GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VII, Partners VII, Opps II, Opps II GP and Schwab collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of 1,041,488 shares of Common Stock and 157,740 shares of Common Stock issuable upon the exercise of immediately exercisable warrants (“Warrants”) held by Ventures VII. Partners VII is the sole general partner of Ventures VII and Schwab and Parmar are the managing members of Partners VII. Each of Partners VII, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VII.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 157,740 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

2 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

5AM Partners VII, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨(b) x (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,199,228 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

1,199,228 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,199,228 (2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

4.1% (3)

12.

Type of Reporting Person (See Instructions)

 

OO       

       
(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of 1,041,488 shares of Common Stock and 157,740 shares of Common Stock issuable upon the exercise of Warrants held by Ventures VII. Partners VII is the sole general partner of Ventures VII and Schwab and Parmar are the managing members of Partners VII. Each of Partners VII, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VII.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 157,740 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

3 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

5AM Opportunities II, L.P.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) x (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

483,356 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

483,356 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

483,356 (2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

1.6% (3)

12.

Type of Reporting Person (See Instructions)

 

PN

       
(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of 430,776 shares of Common Stock and 52,580 shares of Common Stock issuable upon the exercise of Warrants held by Opps II. Opps II GP is the sole general partner of Opps II and Schwab and Parmar are the managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 52,580 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

4 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

5AM Opportunities II (GP), LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) x (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

483,356 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

483,356 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

483,356(2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

1.6% (3)

12.

Type of Reporting Person (See Instructions)

 

OO

       
(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of 430,776 shares of Common Stock and 52,580 shares of Common Stock issuable upon the exercise of Warrants held by Opps II. Opps II GP is the sole general partner of Opps II and Schwab and Parmar are the managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 52,580 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

5 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

Andrew J. Schwab

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) (b) (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,682,584 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

1,682,584 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,682,584 (2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

5.7% (3)

12.

Type of Reporting Person (See Instructions)

 

IN

       
(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of (i) 1,041,488 shares of Common Stock and 157,740 shares of Common Stock issuable upon the exercise of Warrants held by Ventures VII and (ii) 430,776 shares of Common Stock and 52,580 shares of Common Stock issuable upon the exercise of Warrants held by Opps II. Partners VII is the sole general partner of Ventures VII and Opps II GP is the sole general partner of Opps II. Schwab and Parmar are the managing members of each of Partners VII and Opps II GP. Each of Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VII and Opps II.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 210,320 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

6 

 

 

CUSIP No.   252828108
1.

Names of Reporting Persons

 

Kush Parmar

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) (b) (1)

3. SEC Use Only
4.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

1,682,584 (2)

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

1,682,584 (2)

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,682,584 (2)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    
11.

Percent of Class Represented by Amount in Row (9)

 

5.7% (3)

12.

Type of Reporting Person (See Instructions)

 

IN

       
(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
  
(2)Consists of (i) 1,041,488 shares of Common Stock and 157,740 shares of Common Stock issuable upon the exercise of Warrants held by Ventures VII and (ii) 430,776 shares of Common Stock and 52,580 shares of Common Stock issuable upon the exercise of Warrants held by Opps II. Partners VII is the sole general partner of Ventures VII and Opps II GP is the sole general partner of Opps II. Schwab and Parmar are the managing members of each of Partners VII and Opps II GP. Each of Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VII and Opps II.
  
(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) 210,320 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

 

7 

 

 

Item 1.
  (a)

Name of Issuer

 

Dianthus Therapeutics, Inc.

  (b)

Address of Issuer’s Principal Executive Offices

 

7 Times Square, 43rd Floor

New York, NY 10036

 
Item 2.
  (a)

Name of Person Filing

 

5AM Ventures VII, L.P. (“Ventures VII”)

5AM Partners VII, LLC (“Partners VII”)

5AM Opportunities II, L.P. (“Opps II”)

5AM Opportunities II (GP), LLC (“Opps II GP”)

Andrew J. Schwab (“Schwab”)

Dr. Kush Parmar (“Parmar”)

  (b)

Address of Principal Business Office or, if none, Residence

 

c/o 5AM Ventures

501 Second Street, Suite 350

San Francisco, CA 94107

 

  (c) Citizenship    
    Entities: Ventures VII -  Delaware
      Partners VII -  Delaware
      Opps II -  Delaware
      Opps II GP -  Delaware
           
    Individuals: Schwab -  United States
      Parmar - United States

 

  (d)

Title of Class of Securities

 

Common Stock, $0.001 par value (“Common Stock”)

  (e)

CUSIP Number

 

252828108

 
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable

 

8 

 

 

Item 4. Ownership

 

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of February 14, 2024:

 

Reporting
Persons
  Shares Held
Directly
   Sole
Voting
Power
   Shared
Voting
Power
   Sole
Dispositive
Power
   Shared
Dispositive
Power
   Beneficial
Ownership
   Percentage of
Class (3)
 
Ventures VII (1)   1,199,228    0    1,199,228    0    1,199,228    1,199,228    4.1%
Partners VII (1)   0    0    1,199,228    0    1,199,228    1,199,228    4.1%
Opps II (2)   483,356    0    483,356    0    483,356    483,356    1.6%
Opps II GP (2)   0    0    483,356    0    483,356    483,356    1.6%
Schwab (1)(2)   0    0    1,682,584    0    1,682,584    1,682,584    5.7%
Parmar (1)(2)   0    0    1,682,584    0    1,682,584    1,682,584    5.7%

 

(1)Includes 1,041,488 shares of Common Stock and 157,740 shares of Common Stock issuable upon the exercise of Warrants held by Ventures VII. Partners VII is the sole general partner of Ventures VII and Schwab and Parmar are the managing members of Partners VII. Each of Partners VII, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VII.

 

(2)Includes 430,776 shares of Common Stock and 52,580 shares of Common Stock issuable upon the exercise of Warrants held by Opps II. Opps II GP is the sole general partner of Opps II and Schwab and Parmar are the managing members of Opps II GP. Each of Opps II GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opps II.

 

(3)This percentage is calculated based upon the sum of (i) 14,817,696 shares of common stock, as reported in the Issuer’s pre-effective amendment No.1 to Form S-3 on Form S-1 Registration Statement as filed on December 21, 2023, (ii) 14,500,500 shares of common stock sold pursuant to a private placement as reported by the Issuer in a Form 8-K as filed on January 22, 2024, and (iii) shares issuable upon the exercise of the Warrants described above, as applicable.

 

Item 5. Ownership of Five Percent or Less of a Class
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
  Not applicable
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
   
  Not applicable
   
Item 8. Identification and Classification of Members of the Group
   
  Not applicable
 
Item 9. Notice of Dissolution of Group
   
  Not applicable

 

Item 10. Certification
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

 

9 

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2024

 

5AM Ventures VII, L.P. 5AM Partners VII, LLC
 
By: 5AM Partners VII, LLC By: /s/ Andrew J. Schwab
its General Partner     Name: Andrew J. Schwab
    Title: Managing Member  
By: /s/ Andrew J. Schwab  
  Name: Andrew J. Schwab  
  Title: Managing Member  
   
5AM Opportunities II, L.P. 5AM Opportunities II (GP), LLC
   
By: 5AM Opportunities II (GP), LLC By: /s/ Andrew J. Schwab
its General Partner   Name: Andrew J. Schwab
    Title: Managing Member
By: /s/ Andrew J. Schwab  
  Name: Andrew J. Schwab  
  Title: Managing Member  

 

/s/ Andrew J. Schwab  
Andrew J. Schwab  
   
/s/ Dr. Kush Parmar  
Dr.  Kush Parmar    

 

  ATTENTION  
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

 

10 

 

 

Exhibit(s):

 

AJoint Filing Agreement

 

11 

 

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Dianthus Therapeutics, Inc. is filed on behalf of each of us.

 

Dated: February 14, 2024

 

5AM Ventures VII, L.P. 5AM Partners VII, LLC
   
By: 5AM Partners VII, LLC By: /s/ Andrew J. Schwab
its General Partner   Name: Andrew J. Schwab
    Title: Managing Member
By: /s/ Andrew J. Schwab  
  Name: Andrew J. Schwab  
  Title: Managing Member    
 
5AM Opportunities II, L.P. 5AM Opportunities II (GP), LLC
   
By: 5AM Opportunities II (GP), LLC By: /s/ Andrew J. Schwab
its General Partner Name: Andrew J. Schwab
    Title: Managing Member
By: /s/ Andrew J. Schwab  
  Name: Andrew J. Schwab  
  Title: Managing Member    

 

/s/ Andrew J. Schwab  
Andrew J. Schwab  
   
/s/ Dr. Kush Parmar  
Dr.  Kush Parmar  

 

 


Magenta Therapeutics (NASDAQ:MGTA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Magenta Therapeutics Charts.
Magenta Therapeutics (NASDAQ:MGTA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Magenta Therapeutics Charts.